PLUS1
2.36
0.09 (3.96%)
0.09 (3.96%)
Upgrade to Real-Time
Afterhours
| Volume | 99,366 |
|
|||||
| News | - | ||||||
| Day High | 2.35 | Low High |
|||||
| Day Low | 2.15 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxxinity Inc | VAXX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.09 | 3.96% | 2.36 | 18:44:57 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.22 | 2.15 | 2.35 | 2.27 | 2.27 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,226 | 99,366 | $ 2.23 | $ 221,365 | - | 1.51 - 22.77 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:44:57 | 15 | $ 2.25 | USD |
Period:
Draw Mode:
Vaxxinity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 297.42M | 126.02M | 33.87M | $ 66.00k | $ - | -1.80 | -1.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 652.29k | 8.80% |
Vaxxinity News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VAXX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.31 | 2.52 | 2.14 | 2.35 | 216,413 | 0.05 | 2.16% |
| 1 Month | 1.85 | 2.54 | 1.5701 | 2.07 | 310,095 | 0.51 | 27.57% |
| 3 Months | 4.17 | 5.3225 | 1.51 | 2.34 | 394,054 | -1.81 | -43.41% |
| 6 Months | 5.39 | 8.35 | 1.51 | 5.21 | 636,204 | -3.03 | -56.22% |
| 1 Year | 16.90 | 22.77 | 1.51 | 6.61 | 567,620 | -14.54 | -86.04% |
| 3 Years | 16.90 | 22.77 | 1.51 | 6.61 | 567,620 | -14.54 | -86.04% |
| 5 Years | 16.90 | 22.77 | 1.51 | 6.61 | 567,620 | -14.54 | -86.04% |
Vaxxinity Description
| Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. |
